much made it very difficult for doctors to recommend now the j&j vaccine, which is unfortunate because it is a very good vaccine in two doses and has even some advantages over mrna in terms of, i think, more durable and longer lasting protection because it stimulates a type of cell called cda positive cells. with the acip coming out with that statement it s going to be very hard to kind of walk it back. so right now i think a lot of the emphasis for the j&j vaccine is to try to do damage control to make certain that that doesn t contaminate enthusiasm for this vaccine globally because we really need this along with our vaccine and others to really stop the rise of new variants coming out of the global south out of africa, south asia and latin america. so vaccinating the world is going to be the big challenge in 2022. dr. hotez, antonia and gary, thank you all. appreciate it.